Angiocrine Bioscience
San Diego, US · Delaware corporation · 1 known investors
Find your way into Angiocrine Bioscience
45 people in our graph share verified history with the Angiocrine Bioscience team — schools, employers, funds. One of them is your warm intro.
Michele Colucciunlockedknows John T Lomoro · together at Biotia (overlapped)
×4knows the team · via Kyriba
knows the team · via Biotia
knows the team · via DJO
×4knows the team · via St. Cloud State University
knows the team · via Tioga Pharmaceuticals, Inc.
Angiocrine Bioscience is a biotechnology company focused on developing therapies, presenting its work under a science-driven mission to cure disease.
Founders & leadership
JT
John T LomoroinChief Financial Officer/TreasurerJohn T Lomoro is Chief Financial Officer and Treasurer of Angiocrine Bioscience, a biotechnology company developing disease-targeting therapies. He brings more than 25 years of accounting and finance experience across public and private companies in software, manufacturing, pharmaceuticals, and technology, including five years at Ernst & Young and approximately ten years in early-stage companies with international operations.
PW
Paul W FinneganPresident/Chief Executive Officer
JR
John R JaskowiakChief Operating Officer/Secretary
MC
Marc CohenNamed on SEC filing
JJ
Jeff JonasNamed on SEC filing
Board
DP
David ParkinsonBoard director
JL
Jeffrey L PortBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$60.2M disclosed across 2 rounds · 2021–2025
▶$2.1MraisedSep 2025 · 16 investors · BiotechnologyRule 506(b)
▶$2.1MraisedSep 2025 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David ParkinsonDirector
- Jeffrey L PortDirector
- John T LomoroExecutive Officer
- Paul W FinneganExecutive Officer, Director
- John R JaskowiakExecutive Officer
- Offering amount
- $3M
- Amount sold
- $2.1M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$58.1MraisedOct 2021 · 78 investors · BiotechnologyRule 506(b)
▶$58.1MraisedOct 2021 · 78 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Marc CohenDirector
- Jeff JonasDirector
- John JaskowiakExecutive Officer
- John LomoroExecutive Officer
- David ParkinsonDirector
- Paul FinneganExecutive Officer, Director
- Jeffrey PortDirector
- Offering amount
- $99.4M
- Amount sold
- $58.1M
- Sales commissions
- $4.4M
- Placement agents
- BOFA SECURITIES, INC.
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Globaldata15 shared keywordsGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
Active Anonymous Professional Network9 shared keywordsBlind is an anonymous online community where verified professionals discuss workplace topics, pay, layoffs and job moves.
Companies competing with Angiocrine Bioscience for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $189.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $185.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Angiocrine Bioscience do?
- Angiocrine Bioscience is a biotechnology company focused on developing therapies, presenting its work under a science-driven mission to cure disease.
- Who are Angiocrine Bioscience's investors?
- Angiocrine Bioscience's investors include Good Growth Capital.
- How much funding has Angiocrine Bioscience raised?
- Angiocrine Bioscience has disclosed $60.2M raised across 2 rounds.
- Where is Angiocrine Bioscience headquartered?
- Angiocrine Bioscience is headquartered in San Diego, US.